P

Progressive Clinical Research | San Antonio, TX

Research site
(Unclaimed)
Location
1973 NW Loop 410, San Antonio, Texas, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

21 of 94
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Placebo
Drug: Ritlecitinib

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...

Enrolling
Atopic Dermatitis
Drug: Lebrikizumab

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Enrolling
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/o...

Enrolling
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (A...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: LY3454738

The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatiti...

Enrolling
Atopic Dermatitis
Healthy
Drug: Placebo
Drug: Prednisone

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Invitation-only
Vitiligo
Drug: Placebo
Drug: Upadacitinib

The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children with Atopic Dermatitis. This is a randomized, double-b...

Active, not recruiting
Atopic Dermatitis
Drug: Ruxolitinib
Drug: Vehicle Cream

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Povorcitinib
Drug: Placebo

The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and...

Enrolling
Alopecia, Androgenetic
Drug: Clascoterone 5% solution
Drug: Vehicle solution

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Placebo
Drug: Upadacitinib

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atop...

Enrolling
Atopic Dermatitis
Drug: ADX-914
Drug: Placebo

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Invitation-only
Alopecia Areata
Drug: CTP-543

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine calle...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo matching Spesolimab Formulation 2
Drug: Placebo matching Spesolimab Formulation 1

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-...

Active, not recruiting
Scalp Psoriasis
Plaque Psoriasis
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate...

Enrolling
Moderate Plaque Psoriasis
Drug: Guselkumab
Drug: Placebo

The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).

Active, not recruiting
Atopic Dermatitis (AD)
Drug: Ruxolitinib Cream

Trial conditions

Dermatitis (30 trials)
Atopic Dermatitis (29 trials)
Eczema (26 trials)
Psoriasis (19 trials)
Acne Vulgaris (8 trials)
Alopecia (6 trials)
Alopecia Areata (6 trials)
Hidradenitis (6 trials)
Hidradenitis Suppurativa (6 trials)
Vitiligo (5 trials)

And 19 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems